z-logo
open-access-imgOpen Access
Prognostic and Clinicopathologic Significance of Discoidin Domain Receptors in Different Human Malignancies: A Meta-Analysis
Author(s) -
Ferns Gordon A.,
Shabanian Sheida,
Shams Abadi Milad Shahini,
Farhat Ahmadshah,
Arjmand Mohammad-Hassan
Publication year - 2021
Publication title -
gastrointestinal tumors
Language(s) - English
Resource type - Journals
eISSN - 2296-3766
pISSN - 2296-3774
DOI - 10.1159/000517503
Subject(s) - research article
Background: Discoidin domain receptors (DDRs) belong to the receptor tyrosine kinases family and are activated by different types of collagens, which play roles in various physiological processes. An abnormal expression of DDRs is reported in different types of cancers. Despite many reports about the association and roles of high DDR expression levels in cancers, the prognostic values of DDRs are still unclear. This meta-analysis was performed to evaluate the prognostic effect of DDRs in different tissue cancers. Method: A literature search was performed in several related databases to find eligible English articles. Based on our research, 20 appropriate studies with 2,602 patients were selected till October 5, 2020. The pooled hazard ratio (HR) with a corresponding 95% confidence interval (CI) was computed to evaluate the strength of correlation between DDRs and survival of cancer patients. Result: Pooling results showed that a high DDR expression was significantly associated with poorer overall survival (OS) (HR = 1.304, 95% CI 1.007–1.69, p = 0.04). Subgroup analysis based on cancer type revealed a significant link between a high DDR expression level and poor OS both in gastrointestinal (pooled HR = 1.78, 95% CI 1.214–2.624, p = 0.003) and urological cancers (pooled HR = 1.42, 95% CI 1.062–1.82, p = 0.018). Conclusion: Our meta-analysis results suggest that high DDRs expression has the potential to be used as a biomarker of poor prognosis in cancers.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here